Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs.
Employees: 51-200
Founded date: 2007
Investors 3
| Date | Name | Website |
| - | Spur Capit... | spurcapita... |
| 23.03.2023 | Avoro Capi... | avorocapit... |
| 09.06.2023 | Hercules C... | htgc.com |
Mentions in press and media 6
| Date | Title | Description |
| 26.08.2024 | Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor | Appoints Axel Bolte, MBA, MSc, to Board Director and Stephanie Oestreich, PhD, MPA, to Board Observer SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–August 26, 2024– Opna Bio announced that it has dosed the first patient with OPN-6602, a poten... |
| 12.08.2024 | Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights | SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the... |
| 12.08.2024 | Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights | SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 12, Ocumension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the... |
| 03.03.2021 | Iveric Bio Reports Fourth Quarter and Year End 2020 Operational Highlights and Financial Results | NEW YORK--(BUSINESS WIRE)--Mar 3, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the fourth quarter and full year ended December 31, 2020 and provided a general business update. The Company also a... |
| - | Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NEW YORK--(BUSINESS WIRE)--Mar 16, 2021-- IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on March 15, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to a newly-hired, non-ex... |
| - | Iveric Bio to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Wednesday, March 3, 2021 | NEW YORK--(BUSINESS WIRE)--Feb 24, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its fourth quarter and full year 2020 financial and operating results on Wednesday, March 3, 2021. Following the announcement, the... |